Kailera Therapeutics, Inc. (NASDAQ:KLRA) Stock Has Average Target Price of $42.75

Key Points

• Analyst sentiment is moderately bullish: Eight firms give Kailera Therapeutics a consensus “Moderate Buy” rating, with an average 12-month price target of $42.75. Ratings include five buys, one strong buy, one hold, and one sell.
• The stock has declined significantly: KLRA opened at $10.00, down 5%, near its one-year low of $9.76 and well below its $28.23 high. Weiss Ratings also downgraded the company’s sell rating from “d” to “d-.”
• Recent results missed expectations while institutions added positions: Kailera reported a quarterly loss of $1.09 per share versus the expected $0.74 loss, while several institutional investors—including Atlas Venture and Frazier Life Sciences—established new stakes.

Shares of Kailera Therapeutics, Inc. (NASDAQ:KLRA - Get Free Report) have earned an average rating of "Moderate Buy" from the eight ratings firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, five have given a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $42.75.

Separately, Weiss Ratings cut Kailera Therapeutics from a "sell (d)" rating to a "sell (d-)" rating in a research note on Tuesday.

Kailera Therapeutics Trading Down 5.0%

NASDAQ KLRA opened at $10.00 on Friday. The stock has a market capitalization of $1.30 billion and a price-to-earnings ratio of -0.00. The company has a 50 day simple moving average of $15.14. Kailera Therapeutics has a one year low of $9.76 and a one year high of $28.23.

Kailera Therapeutics (NASDAQ:KLRA - Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.35). As a group, analysts forecast that Kailera Therapeutics will post -3.89 EPS for the current fiscal year.

Hedge Funds Weigh In On Kailera Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. State Street Corp purchased a new stake in shares of Kailera Therapeutics during the second quarter worth approximately $19,126,000. Tidal Investments LLC purchased a new position in Kailera Therapeutics in the second quarter worth approximately $309,000. Squarepoint Ops LLC acquired a new position in Kailera Therapeutics during the 2nd quarter worth approximately $993,000. Frazier Life Sciences Management L.P. purchased a new stake in shares of Kailera Therapeutics in the 2nd quarter valued at approximately $24,233,000. Finally, Atlas Venture Life Science Advisors LLC purchased a new stake in shares of Kailera Therapeutics in the 2nd quarter valued at approximately $113,923,000.

Kailera Therapeutics Company Profile

Kailera Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for obesity and other chronic metabolic diseases. The company's research is centered on therapies designed to address weight management and related health conditions.

Kailera's pipeline includes ecnoglutide, an investigational, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for potential use in obesity and metabolic disorders. The company continues to advance clinical development and assess additional opportunities in the metabolic disease sector.

Kailera Therapeutics is focused primarily on research and development activities, with its programs intended for potential commercialization in international markets subject to clinical, regulatory and other approvals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.